Follow up approaches in thyroid cancer: a risk adapted paradigm.
暂无分享,去创建一个
[1] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[2] R. Tuttle,et al. Papillary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.
[3] W. Wiersinga,et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.
[4] Gerard M Doherty,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.
[5] Mithat Gonen,et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.
[6] J. Shah,et al. Low-risk differentiated thyroid cancer: The need for selective treatment , 1997, Annals of Surgical Oncology.
[7] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[8] J. Watkinson,et al. The British Thyroid Association guidelines for the management of thyroid cancer in adults , 2004, Nuclear medicine communications.
[9] A. Pinchera,et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[10] A. Oberg,et al. Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.
[11] S. Larson,et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.
[12] A. Pinchera,et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. , 2001, The Journal of clinical endocrinology and metabolism.
[13] R. Kloos,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .
[14] H. Gharib,et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[15] J. Shah,et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 , 2000, Cancer.
[16] D. Dean,et al. Prognostic indicators in differentiated thyroid carcinoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.
[17] I. Hay,et al. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. , 1996, Surgical oncology clinics of North America.